Roche's Giredestrant Misses Key Goal in First-Line Breast Cancer Study

Roche (RHHBY) reported that giredestrant plus palbociclib failed to meet the primary progression-free survival (PFS) endpoint in a Phase III first-line breast cancer study. The combo showed a numerical but not statistically significant improvement, suggesting limited near-term upside for the program and potential headwinds for the company's oncology outlook.

Analysis

Roche (RHHBY) reported that giredestrant plus palbociclib failed to meet the primary progression-free survival (PFS) endpoint in a Phase III first-line breast cancer study. The combo showed a numerical but not statistically significant improvement, suggesting limited near-term upside for the program and potential headwinds for the company's oncology outlook.